TARGAXAN® has been shown to reduce the burden on healthcare systems when used to prevent the recurrence of overt hepatic encephalopathy 1‑3
The use of rifaximin-α to manage UK & Irish patients with hepatic encephalopathy has shown reductions in hospital resource utilisation. Select a parameter to find out more.
UK/XIF5/0719/0523 DOP: October 2019